AnaptysBio (ANAB) Aktie Kurs
AnaptysBio Kurs
Omsætningen er vokset med 36,8 % om året de seneste 12 år til 234,60 Mio. USD. AnaptysBios nettoavance ligger på -5,6 %, op fra -91,5 % for flere år siden. Analytikernes mediankursmål er 75,50 USD, hvilket er over den aktuelle kurs med 50,4 %. Af 15 analytikere anbefaler 14 køb — den samlede vurdering er Køb.
AnaptysBio aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
AnaptysBio aktie og aktieanalyse
Hyppigt stillede spørgsmål om AnaptysBio-aktien
The business model of AnaptysBio Inc is focused on discovering and developing novel antibody-based therapeutics for inflammation and immuno-oncology. With a strong emphasis on research and development, AnaptysBio utilizes its proprietary technology platform to generate highly specific therapeutic antibodies. These antibodies are aimed at targeting and modulating key immune system pathways to address various diseases, including inflammatory disorders, severe allergies, and certain types of cancers. By leveraging its expertise in antibody engineering and design, AnaptysBio aims to deliver innovative treatments that can improve patient outcomes and provide value to healthcare providers.
AnaptysBio Inc is primarily active in the biotechnology industry.
The main competitors of AnaptysBio Inc in the market are Regeneron Pharmaceuticals, Inc., Amgen Inc., and Novartis AG.
AnaptysBio Inc is a biotechnology company based in San Diego, California. Established in 2005, the company specializes in the discovery and development of therapeutic antibodies to address unmet medical needs. With a focus on inflammation, immuno-oncology, and rare diseases, AnaptysBio Inc utilizes its proprietary antibody discovery platform to identify and develop potential treatments. The company has forged collaborations with leading pharmaceutical companies and has a diverse pipeline of antibody candidates. AnaptysBio Inc's commitment to innovation and expertise in antibody-based therapies has positioned them as a prominent player in the biotech industry.
AnaptysBio Inc has achieved several significant milestones. The company has successfully developed novel antibody therapeutics for various severe diseases, including atopic dermatitis and peanut allergies. Additionally, AnaptysBio Inc has also entered into strategic collaborations with renowned pharmaceutical companies to further advance its drug pipeline. The company's dedication to research and development has led to the successful completion of multiple clinical trials, demonstrating their commitment to improving patient outcomes. With their innovative approach and strong partnerships, AnaptysBio Inc continues to pave the way in the field of biotechnology.
AnaptysBio Inc is primarily present in the United States.
AnaptysBio Inc represents a commitment to scientific innovation and excellence in the field of biotechnology. Its core values include a focus on discovering and developing novel antibody therapeutics to address unmet medical needs. The company strives to create value for patients, healthcare professionals, and shareholders through its cutting-edge research and development efforts. With a corporate philosophy centered around collaboration, AnaptysBio Inc aims to leverage its expertise and partnerships to drive forward breakthrough therapies that have the potential to improve patients' lives and revolutionize healthcare.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 73,67 USD for AnaptysBio-aktien (median: 75,50 USD), svarende til +46,7 % i forhold til seneste kurs. Konsensus bygger på 15 analytikervurderinger.
15 analytikere vurderer i øjeblikket AnaptysBio-aktien: 14 anbefaler køb, 1 hold og 0 salg. For 2026 forventer analytikere, at AnaptysBio genererer omsætning på 138,05 Mio. USD og indtjening pr. aktie på 4,65 USD.
Omregnet til den aktuelle valutakurs handles AnaptysBio-aktien til 44,97 EUR (50,21 USD).
AnaptysBio-aktien (ANAB) er noteret på 5 børser, herunder: NASDAQ (ANAB), London (0HFQ.L), Frankfurt (AN6.F), München (AN6.MU), Düsseldorf (AN6.DU).
AnaptysBio Inc is an innovative biotechnology company that focuses on the discovery and development of new biological therapeutics. The company was founded in 2005 in San Diego, California, and has since gained a leading position in the industry. The business model of AnaptysBio is based on the development of highly effective antibodies with a focus on inflammatory diseases and cancer. The scientists and developers at AnaptysBio use the latest technologies to identify and develop potential candidates in a rapid, precise, and cost-effective approach. AnaptysBio takes a differentiated approach to antibody identification and specializes in the development of biological therapeutics. AnaptysBio has a wide range of products, including Atrmab, ANB020, ANB019, and Etokimab. Atrmab is a nasal administration antibody product developed to treat allergic diseases such as hay fever. ANB020 is an antibody specifically targeting the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease. On the other hand, the antibody ANB019 is being developed as a therapy option for both Generalized Pustular Psoriasis (GPP) and Palmoplantar Pustular Psoriasis (PPP). Etokimab, on the other hand, aims to treat tessin and chronic pruritus. This is a non-specific skin disease characterized by constant itching and tingling. By developing innovative therapies, AnaptysBio is able to achieve significant advancements in the field of biological medicines. These therapeutics will help improve the lives of patients in various stages of the disease. AnaptysBio benefits from serving a small but rapidly growing niche in the industry. There is a high demand for specialized biological medicines, as these medicines are often more effective and better tolerated than traditional medicines and are therefore preferred by many doctors. AnaptysBio finances its business activities through investment capital and strategic partnerships with large pharmaceutical companies. In the early stages of biological therapeutic development, AnaptysBio plays an important role by conducting proof-of-concept studies and demonstrating the potential of new therapeutics. Once the therapeutics move into clinical phases, pharmaceutical companies seek collaborations to conduct joint clinical trials and enter the market. Overall, AnaptysBio is a successful biotech company that is capable of revolutionizing therapy approaches for inflammatory and cancerous diseases. Through collaboration with large pharmaceutical companies and the development of innovative products, AnaptysBio is in a strong position to achieve further growth and success.
forventet-omsætningen for AnaptysBio er 138,05 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for AnaptysBio er 145,89 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for AnaptysBio er i øjeblikket 10,79. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af AnaptysBio-aktien.
Pris-til-salgs-forholdet (P/S) for AnaptysBio er i øjeblikket 11,40. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for AnaptysBio-aktien.
AlleAktien-kvalitetsscore for AnaptysBio er 5/10.
ISIN for AnaptysBio er US0327241065. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for AnaptysBio er A2AJ8C. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for AnaptysBio er ANAB. Tickersymbolet bruges til at handle AnaptysBio-aktier på børsen.
AnaptysBio aktie
AnaptysBio Peer Group
AnaptysBio Ticker
AnaptysBio FIGI
Alle fundamentale data om AnaptysBio i deep dive
Vores aktieanalyse af AnaptysBio-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos AnaptysBio. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: